Last Update 07 Feb 26

Fair value Increased 7.27%

ELAN: New Pet Health Launches And Balance Sheet Progress Will Shape Outlook

Analysts have raised their fair value estimate for Elanco Animal Health by about $1.76 to $25.92, citing higher Street price targets, recent upgrades and Overweight initiations that highlight potential benefits from new product launches, revenue growth efforts and ongoing balance sheet improvement.

Analyst Commentary

Recent research coverage on Elanco Animal Health has leaned constructive, with several firms lifting price targets or initiating and upgrading ratings after reviewing the company’s new product pipeline, revenue initiatives and balance sheet trajectory.

Bullish Takeaways

Bullish analysts lifting price targets into the mid $20s point to potential upside they see relative to current pricing, anchored on expectations around new product launches and margin expansion efforts.
Overweight initiations and upgrades suggest increased confidence in the company’s ability to translate its recent product rollouts into sustained revenue growth rather than one off contributions.
Comments around lower leverage and prospects for further improvement from rising cash flows indicate that some analysts view balance sheet progress as a support for valuation and risk profile.
The clustering of price targets between roughly $24 and $27 signals a tighter range of expectations, which can help investors frame upside and downside scenarios more clearly.

Bearish Takeaways

Even bullish analysts acknowledge challenges in displacing incumbent treatments, which could slow the pace at which new products contribute to revenue and limit how quickly growth assumptions play out.
At least one firm maintains a Neutral stance despite lifting its price target, a reminder that not all analysts are convinced execution on growth initiatives will fully match higher expectations.
The reliance on successful uptake of recent launches creates execution risk, since any delays in adoption or competitive responses could pressure both growth forecasts and the fair value range.
With multiple upgrades and Overweight calls already in place, some investors may question how much of the positive thesis is already reflected in current Street targets, leaving less room for upside surprise.

What's in the News

USDA approval of Befrena, an anti IL31 monoclonal antibody injection for canine allergic and atopic dermatitis, with dosing every 6 to 8 weeks and a planned U.S. launch in the first half of 2026. This expands Elanco's presence in canine dermatology alongside Zenrelia tablets and updated Zenrelia labeling from the FDA that removes a prior risk description tied to modified live virus vaccines while keeping boxed warning timing guidance around vaccination (Key Developments).
Conditional FDA approval for Credelio Quattro CA1 chewable tablets to treat New World screwworm infestations in dogs, the first conditional approval for a companion animal product targeting this parasite. New product labeling is expected in 2026 and the product is positioned alongside existing Credelio Quattro coverage for ticks, fleas, heartworm disease, roundworms, hookworms and tapeworms (Key Developments).
Emergency Use Authorization from the FDA for Credelio CAT to treat New World screwworm infestations in cats, giving veterinarians a treatment option if the fly spreads closer to the U.S. border and addressing a gap where cats historically have had fewer products and fewer vet visits compared to dogs (Key Developments).
Organizational changes under the Elanco Ascend productivity initiative, including an expanded R&D organization in Indianapolis, a proposed closure of a Germany animal facility, a partnership with The Clinglobal Group, manufacturing footprint adjustments and workforce changes affecting about 600 roles. The initiative targets savings of about $25m in 2026 and $60m in 2027 and includes an expected charge of about $175m, of which roughly $130m is cash based (Key Developments).
Planned investment over the next five years to grow U.S. operations, including expanded R&D at the Indianapolis headquarters and OneHealth Innovation District, added spending on U.S. manufacturing sites and further investment in the Kansas monoclonal antibody facility tied to a potential first in class pet health immuno therapeutic that has an accelerated USDA pathway and is expected in the next 2 to 3 years. The company has also stated an intent to pursue smaller tuck under M&A deals to build out the portfolio (Key Developments).

Valuation Changes

The fair value estimate has risen slightly from $24.17 to $25.92 per share, a move of about $1.76.
The discount rate has inched up from 6.96% to 6.98%, a very small change in the assumed risk level.
Revenue growth has eased slightly from 5.36% to 5.28%, reflecting a modestly lower growth assumption.
The net profit margin has fallen significantly from 6.63% to 3.17%, implying a more conservative view on future profitability.
The future P/E has more than doubled, moving from 41.77x to 94.09x, indicating a much higher multiple applied to expected earnings in the updated assumptions.

5 views

Key Takeaways

Strategic divestment and product launches are enhancing financial stability by reducing debt and increasing investment capacity, aiming to improve net margins.
Focus on innovation, balanced portfolio, and geographic expansion is expected to drive revenue growth in pet and farm animal markets, boosting earnings.
FX headwinds, rising operating expenses, and reliance on new product adoption challenge Elanco's revenue stability and profitability amidst international market and leverage risks.

Catalysts

About Elanco Animal Health

An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.What are the underlying business or industry changes driving this perspective?

Elanco anticipates an acceleration in organic constant currency revenue growth of 4% to 6%, driven by innovation and market expansion. This will positively impact revenue growth.
The successful launch of six potential blockbuster products and exceeding innovation revenue targets for 2024 positions Elanco for strong innovation contributions in 2025, expected to increase innovation revenue, positively influencing earnings.
Operational focus on strategic product launches and divesting non-core businesses such as the Aqua division has enabled debt reduction and increased investment capacity, which should improve net margins and financial stability.
Elanco's strategic focus on leveraging their diversified portfolio and geographic expansion, particularly in key growth markets, is anticipated to maintain balanced revenue growth across both pet health and farm animal markets.
An emphasis on ongoing efficiency improvements, through infrastructure optimization and improved product mix, is expected to enable margin expansion from 2026 onwards, boosting long-term earnings potential.

Elanco Animal Health Earnings and Revenue Growth

Elanco Animal Health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Elanco Animal Health's revenue will grow by 4.5% annually over the next 3 years.
Analysts assume that profit margins will shrink from 9.7% today to 3.6% in 3 years time.
Analysts expect earnings to reach $186.7 million (and earnings per share of $0.37) by about September 2028, down from $434.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $213 million in earnings, and the most bearish expecting $99 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 59.8x on those 2028 earnings, up from 19.9x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.5x.
Analysts expect the number of shares outstanding to grow by 0.5% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Elanco Animal Health Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Elanco faces foreign exchange (FX) headwinds, which could negatively impact reported revenue and profits, especially given the stronger U.S. dollar's unfavorable impact on performance metrics. These exchange rate impacts could constrain revenue and adjusted EBITDA margins.
Although market conditions in international farm animal segments are improving, the challenging swine economics in Asia and potential impacts from the strategic Do Different approach could hinder international revenue stability. Any volatility in these areas may affect revenue growth significantly.
Elanco’s significant increase in operating expenses, driven by investments in sales and marketing for product launches, may put pressure on net margins. This near-term headwind might impede the ability to convert top-line growth into increased profitability quickly.
While Elanco has made progress in debt reduction, holding significant net leverage could pose a financial risk if cash flows do not meet expectations, potentially affecting net margins and earnings through increased financial costs or refinancing challenges.
The reliance on achieving rapid adoption of new products like Zenrelia and Credelio Quattro, and the need to penetrate the veterinary clinic market, entail execution risks that could affect the sales ramp-up, impacting growth expectations and future revenue stability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $18.182 for Elanco Animal Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $21.0, and the most bearish reporting a price target of just $14.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $5.1 billion, earnings will come to $186.7 million, and it would be trading on a PE ratio of 59.8x, assuming you use a discount rate of 6.8%.
Given the current share price of $17.35, the analyst price target of $18.18 is 4.6% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Elanco Animal Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Upcoming Launches And Market Developments Will Shape Earnings Expectations This Year